Melanotan II reliably darkens skin, and that is the reason it is used. It also has one of the clearest published harm records of any peptide in this space, including melanoma diagnosed after use, rhabdomyolysis and severe systemic reactions.
Key points
- It is a non-selective melanocortin receptor agonist; pigmentation, nausea, flushing and erections are all on-target effects.
- Case reports describe new or changed melanocytic lesions, including melanoma, in users.
- Rhabdomyolysis and posterior reversible encephalopathy have been reported after use.
- Vials are almost entirely unregulated, unsterile and of unverified content.
What the literature shows
Dermatology case series document eruptive naevi, darkening of existing moles and melanoma diagnosed in melanotan users, with the pigmentary changes complicating clinical surveillance.
Case reports describe rhabdomyolysis requiring hospital admission shortly after injection.
Additional reports link use to severe systemic events including encephalopathy and cardiac symptoms.
Analyses of purchased vials have found incorrect peptide content and evidence of contamination.
What remains unknown
- Whether use causally increases melanoma risk, versus revealing existing lesions, remains unresolved.
- Cumulative dose relationships to reported adverse events are unquantified.
- Long-term effects on melanocyte biology after cessation are unknown.
Safety and monitoring implications
- Any new, changing, asymmetric or bleeding skin lesion needs prompt dermatological assessment, and the practitioner should be told about use.
- Widespread darkening makes self-monitoring of moles substantially less reliable.
- Severe muscle pain with dark urine after injection is a medical emergency.
Cited literature
- 1.Cousen P, Colver G, Helbling I. (2009). Eruptive melanocytic naevi following melanotan injection. British Journal of Dermatology. Find on PubMed
- 2.Ong S, Bowling J. (2012). Melanotan-associated melanoma in situ. Australasian Journal of Dermatology. Find on PubMed
- 3.Ellis R, Kirkham N, Seukeran DC. (2011). Rhabdomyolysis and melanotan II use. Clinical and Experimental Dermatology. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Cosmetic and physique forums
MixedPigmentation results are described as fast and striking, with nausea and flushing after injection treated as routine.
Harm-reduction discussion groups
NegativeRepeated warnings about mole changes, and multiple accounts of users being told by clinicians to stop after a skin check.
Buying Melanotan II in Australia: what to check first
APEDRA does not sell Melanotan II or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.